In vivo effects of a combined 5-HT 1B receptor/SERT antagonist in experimental pulmonary hypertension

Cardiovascular Research

Volumn 85, Issue 3, 2010, Pages 593-603

  Morecroft, Ian ^a   Pang, Louisa ^a   Baranowska, Marta ^b   Nilsen, Margaret ^a   Loughlin, Lynn ^a   Dempsie, Yvonne ^a   Millet, Caroline ^a   MacLean, Margaret R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

5HT 1B; Hypoxia; Pulmonary hypertension; Serotonin; Serotonin transporter

Indexed keywords

CITALOPRAM; LY 393558; SEROTONIN 1B ANTAGONIST; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; VASOCONSTRICTION;

ANIMALS; CELL PROLIFERATION; CITALOPRAM; CYCLIC S-OXIDES; FEMALE; HYPERTENSION, PULMONARY; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN UPTAKE INHIBITORS; THIADIAZINES; VASOCONSTRICTION;

EID: 74249096822     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp306     Document Type: Article

References (26)

1. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51: 1527-1538.
2. Yang XD, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK et al. Dysfunctional smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 2005;96:1053-1063.
3. Dempsie Y, MacLean MR. Pulmonary hypertension: therapeutic targets within the serotonin system. Br J Pharmacol 2008;155:455-462.
4. Dempsie Y, Morecroft I, Welsh DJ, MacRitchie NA, Herold N, Loughlin L et al. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 2008; 117:2928-2937.
5. Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L et al. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 2007;49:232-236.
6. Marcos E, Fadel E, Sanchez O, Humbert M, Dartevelle P, Simonneau G et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004;94:1263-1270.
7. Morecroft I, Heeley RP, Prentice HM, Kirk A, MacLean MR. 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol 1999;128:730-734.
8. Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR et al. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res 2005;97:227-235.
9. Liu YL, Suzuki YJ, Day RM, Fanburg BL. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 2004;95:579-586.
10. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen SB, Sheward J et al. Overexpression of the 5-hydroxytryptamine transporter gene\-effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 2004;109:2150-2155.
11. Mair KM, MacLean MR, Morecroft I, Dempsie Y, Palmer TM. Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br J Pharmacol 2008;155:606-616.
12. Morecroft I, Loughlin L, Nilsen M, Colston J, Dempsie Y, Sheward J et al. Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther 2005;313:539-548.
13. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR. Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension\-converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935. Circ Res 2001;89:1231-1239.
14. Guignabert C, Izikki M, Tu LI, Li ZL, Zadigue P, Barlier-Mur AM et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 2006;98:1323-1330.
15. MacLean MR. Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action? Trends Pharmacol Sci 1999;20:490-495.
16. MacLean MR, Morecroft I. Increased contractile response to 5-hydroxytryptamine(1)-receptor stimulation in pulmonary arteries from chronic hypoxic rats: role of pharmacological synergy. Br J Pharmacol 2001;134: 614-620.
17. Pullar IA, Boot JR, Carney SL, Cohen ML, Colvin EM, Conway RG et al. In vitro activity of LY393558, an inhibitor of the 5-hydroxytryptamine transporter with 5-HT1B/1D/2 receptor antagonist properties. Eur J Pharmacol 2001;432:9-17.
18. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005;111:2812-2819.
19. Damjanoska KJ, Van de Kar LD, Kindel GH, Zhang Y, D'Souza DN, Garcia F et al. Chronic fluoxetine differentially affects 5-hydroxytryptamine2A receptor signaling in frontal cortex, oxytocin-and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus. J Pharmacol Exp Ther 2003;306: 563-571.
20. Pacher P, Ungvari Z, Kecskemeti V, Koller A. Serotonin reuptake inhibitor, fluox-etine, dilates isolated skeletal muscle arterioles. Possible role of altered Ca2+ sensitivity. Br J Pharmacol 1999;127:740-746.
21. Kong EK, Peng L, Chen Y, Yu AC, Hertz L. Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem Res 2002;27:113-120.
22. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I. 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 1996;119:917-930.
23. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141-1150.
24. Eddahibi S, Chaouat A, Morrell N, Fadel E, Fuhrman C, Bugnet AS et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003;108:1839-1844.
25. Willers ED, Newman JH, Loyd JE, Robbins IM, Wheeler LA, Prince MA et al. Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;173:798-802.
26. Kawut SM, Horn EM, Berekashvili KK, Lederer DJ, Widlitz AC, Rosenzweig EB et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 2006;19:370-374.